1
|
Brock EJ, Jackson RM, Boerner JL, Li Q, Tennis MA, Sloane BF, Mattingly RR. Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. PLoS One 2021; 16:e0252314. [PMID: 34048471 PMCID: PMC8162601 DOI: 10.1371/journal.pone.0252314] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 05/13/2021] [Indexed: 12/16/2022] Open
Abstract
Breast ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive ductal carcinoma (IDC). It is still unclear which DCIS will become invasive and which will remain indolent. Patients often receive surgery and radiotherapy, but this early intervention has not produced substantial decreases in late-stage disease. Sprouty proteins are important regulators of ERK/MAPK signaling and have been studied in various cancers. We hypothesized that Sprouty4 is an endogenous inhibitor of ERK/MAPK signaling and that its loss/reduced expression is a mechanism by which DCIS lesions progress toward IDC, including triple-negative disease. Using immunohistochemistry, we found reduced Sprouty4 expression in IDC patient samples compared to DCIS, and that ERK/MAPK phosphorylation had an inverse relationship to Sprouty4 expression. These observations were reproduced using a 3D culture model of disease progression. Knockdown of Sprouty4 in MCF10.DCIS cells increased ERK/MAPK phosphorylation as well as their invasive capability, while overexpression of Sprouty4 in MCF10.CA1d IDC cells reduced ERK/MAPK phosphorylation, invasion, and the aggressive phenotype exhibited by these cells. Immunofluorescence experiments revealed reorganization of the actin cytoskeleton and relocation of E-cadherin back to the cell surface, consistent with the restoration of adherens junctions. To determine whether these effects were due to changes in ERK/MAPK signaling, MEK1/2 was pharmacologically inhibited in IDC cells. Nanomolar concentrations of MEK162/binimetinib restored an epithelial-like phenotype and reduced pericellular proteolysis, similar to Sprouty4 overexpression. From these data we conclude that Sprouty4 acts to control ERK/MAPK signaling in DCIS, thus limiting the progression of these premalignant breast lesions.
Collapse
MESH Headings
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Intraductal, Noninfiltrating/genetics
- Carcinoma, Intraductal, Noninfiltrating/metabolism
- Cell Line, Tumor
- Cells, Cultured
- Female
- Humans
- Immunoblotting
- Immunohistochemistry
- Intracellular Signaling Peptides and Proteins/genetics
- Intracellular Signaling Peptides and Proteins/metabolism
- Mitogen-Activated Protein Kinase 1/genetics
- Mitogen-Activated Protein Kinase 1/metabolism
- Mitogen-Activated Protein Kinase 3/genetics
- Mitogen-Activated Protein Kinase 3/metabolism
- Nerve Tissue Proteins/genetics
- Nerve Tissue Proteins/metabolism
Collapse
Affiliation(s)
- Ethan J. Brock
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United states of America
| | - Ryan M. Jackson
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United states of America
| | - Julie L. Boerner
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United states of America
| | - Quanwen Li
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United states of America
| | - Meredith A. Tennis
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, United states of America
| | - Bonnie F. Sloane
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United states of America
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United states of America
| | - Raymond R. Mattingly
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United states of America
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, United states of America
| |
Collapse
|
2
|
Thakur A, Kondadasula SV, Ji K, Schalk DL, Bliemeister E, Ung J, Aboukameel A, Casarez E, Sloane BF, Lum LG. Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE). Cancer Immunol Immunother 2020; 70:633-656. [PMID: 32865605 DOI: 10.1007/s00262-020-02692-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 08/04/2020] [Indexed: 10/23/2022]
Abstract
Adoptive transfer of Bispecific antibody Armed activated T cells (BATs) showed promising anti-tumor activity in clinical trials in solid tumors. The cytotoxic activity of BATs occurs upon engagement with tumor cells via the bispecific antibody (BiAb) bridge, which stimulates BATs to release cytotoxic molecules, cytokines, chemokines, and other signaling molecules extracellularly. We hypothesized that the release of BATs Induced Tumor-Targeting Effectors (TITE) by this complex interaction of T cells, bispecific antibody, and tumor cells may serve as a potent anti-tumor and immune-activating immunotherapeutic approach. In a 3D tumorsphere model, TITE showed potent cytotoxic activity against multiple breast cancer cell lines compared to control conditioned media (CM): Tumor-CM (T-CM), BATs-CM (B-CM), BiAb Armed PBMC-CM (BAP-CM) or PBMC-CM (P-CM). Multiplex cytokine analysis showed high levels of Th1 cytokines and chemokines; phospho-protein signaling array data suggest that the prominent JAK1/STAT1 pathway may be responsible for the induction and release of Th1 cytokines/chemokines in TITE. In xenograft breast cancer models, IV injections of 10× concentrated TITE (3×/week for 3 weeks; 150 μl TITE/injection) was able to inhibit tumor growth significantly (ICR/scid, p < 0.003; NSG p < 0.008) compared to the control mice. We tested the key components of the TITE for immune activating and anti-tumor activity individually and in combinations, the combination of IFN-γ, TNF-α and MIP-1β recapitulates the key activities of the TITE. In summary, master mix of active components of BATs-Tumor complex-derived TITE can provide a clinically controllable cell-free platform to target various tumor types regardless of the heterogeneous nature of the tumor cells and mutational tumor.
Collapse
Affiliation(s)
- Archana Thakur
- Bone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA.
| | - Sri Vidya Kondadasula
- Departments of Oncology and Medicine, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA
| | - Kyungmin Ji
- Department of Pharmacology, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA
| | - Dana L Schalk
- Bone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA
| | - Edwin Bliemeister
- Bone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA
| | - Johnson Ung
- Bone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA
| | - Amro Aboukameel
- Departments of Oncology and Medicine, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA
| | - Eli Casarez
- Bone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA
| | - Bonnie F Sloane
- Department of Pharmacology, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA
| | - Lawrence G Lum
- Bone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA
| |
Collapse
|
3
|
Thakur A, Yarlagadda S, Ji K, Schalk DL, Ung J, Bliemeister ET, Aboukameel A, Casarez E, Sloane BF, Lum LG. Abstract 5036: Induction of highly efficacious anti-tumor activity and modulation of tumor microenvironment: Cell-free off the shelf therapeutic modality. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-5036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Adoptive transfer of Bispecific antibody Armed activated T cells (BATs) show promising anti-tumor activity in clinical trials in solid tumors. The cytotoxic activity of BATs occur upon engagement with tumor cells via the bispecific antibody bridge which stimulates BATs to release not only the lytic and cytotoxic molecules (perforin/granzyme) but also cytokines, chemokines and other signaling molecules extracellularly. We hypothesized that the release of extracellular soluble factors by this complex interaction of T cells, bispecific antibody, and tumor cells may serve as a potent anti-tumor and immune activating conditioned media (CM). In a 3D tumorsphere model, tumor+BATs-CM (n=10) showed potent cytotoxicity (p<0.001) against multiple breast (MDA-MB-231, BT-20, SK-BR-3 and MCF-7) and other cancer cell lines (p<0.001) compared to control tumor-CM or BATs-CM. Tumor+BATs-CM (n=6) was able to reduce the proportion of CD44hi/CD24lo cancer stem like cells to 0.7% compared to 4.9% in control CM. The addition of tumor+BATs-CM decreased the proportions of T regulatory cells (5% to 1.1%; p<0.02) and myeloid derived suppressor cells (3.8% to 1.2%; p<0.03), but increased activation and proliferation of effector T cells in 3D cultures compared to control CM (n=3). Size based CM factionation showed that most activity is retained in the <50kDa but >10kDa fraction. Multiplex analysis showed high levels of IL-2, IL-15, IFN-γ, TNF-α, GM-CSF, granszyme B (GZB), IL-13, MIP-1β, IP-10, MIG and RANTES. These factors are likely responsible for the cytolytic and immune activating effects. Phospho-specific signaling protein arrays showed enhanced JAK1/STAT-1/STAT-5A, Rac/cdc42/STIM-1) pathways in tumor+BATs-CM (n=3). Exosomal microRNA (miR) in tumor+BAT-CM showed higher expression of several miRs that are associated with T cell function and activation compared to control CM (n=2). Simulations using cocktails of multiple cytokines were done to test anti-tumor activity, IFN-γ/TNF-α/GZB showed potent cytotoxicity directed at breast (58-78%) and pancreatic cancer (50-72%) cell lines compared to 45-65%, 20-27%, 18-25% with IFN-γ, TNF-α and GZB individually, respectively. In a xenograft breast cancer model, IV and intra-tumoral injections of 10x concentrated tumor+BAT-CM (3x/week for 4 weeks;150μl CM/injection) was able to inhibit tumor growth significantly (p<0.01) compared to the control CM treated mice (n=10 mice/group). Therapeutic advantages of CM include: 1) a ready off-the-shelf product; 2) a decrease in regulatory and manufacturing costs. In summary, BATs-Tumor complex derived CM provides a clinically controllable cell-free platform to target various tumor types with diverse anti-cancer immune activating mediators regardless of the heterogeneous nature of the tumor cells and mutational burden as a novel and potent off-the-shelf therapeutic modality.
Citation Format: Archana Thakur, SriVidya Yarlagadda, Kyungmin Ji, Dana L. Schalk, Johnson Ung, Edwin T. Bliemeister, Amro Aboukameel, Eli Casarez, Bonnie F. Sloane, Lawrence G. Lum. Induction of highly efficacious anti-tumor activity and modulation of tumor microenvironment: Cell-free off the shelf therapeutic modality [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5036.
Collapse
Affiliation(s)
- Archana Thakur
- 1University of Virginia Cancer Center, Charlottesville, VA
| | | | | | - Dana L. Schalk
- 1University of Virginia Cancer Center, Charlottesville, VA
| | - Johnson Ung
- 1University of Virginia Cancer Center, Charlottesville, VA
| | | | | | - Eli Casarez
- 1University of Virginia Cancer Center, Charlottesville, VA
| | | | | |
Collapse
|
4
|
Brock EJ, Ji K, Shah S, Mattingly RR, Sloane BF. In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ. J Mammary Gland Biol Neoplasia 2019; 24:1-15. [PMID: 30056557 PMCID: PMC6641861 DOI: 10.1007/s10911-018-9405-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 07/13/2018] [Indexed: 12/11/2022] Open
Abstract
About one fourth of all newly identified cases of breast carcinoma are diagnoses of breast ductal carcinoma in situ (DCIS). Since we cannot yet distinguish DCIS cases that would remain indolent from those that may progress to life-threatening invasive ductal carcinoma (IDC), almost all women undergo aggressive treatment. In order to allow for more rational individualized treatment, we and others are developing in vitro models to identify and validate druggable pathways that mediate the transition of DCIS to IDC. These models range from conventional two-dimensional (2D) monolayer cultures on plastic to 3D cultures in natural or synthetic matrices. Some models consist solely of DCIS cells, either cell lines or primary cells. Others are co-cultures that include additional cell types present in the normal or cancerous human breast. The 3D co-culture models more accurately mimic structural and functional changes in breast architecture that accompany the transition of DCIS to IDC. Mechanistic studies of the dynamic and temporal changes associated with this transition are facilitated by adapting the in vitro models to engineered microfluidic platforms. Ultimately, the goal is to create in vitro models that can serve as a reproducible preclinical screen for testing therapeutic strategies that will reduce progression of DCIS to IDC. This review will discuss the in vitro models that are currently available, as well as the progress that has been made using them to understand DCIS pathobiology.
Collapse
MESH Headings
- Breast/pathology
- Breast Neoplasms/drug therapy
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Intraductal, Noninfiltrating/drug therapy
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Cell Line, Tumor
- Coculture Techniques/methods
- Drug Screening Assays, Antitumor/methods
- Female
- Humans
- Neoplasm Invasiveness/pathology
- Neoplasm Invasiveness/prevention & control
- Primary Cell Culture/methods
Collapse
Affiliation(s)
- Ethan J Brock
- Program in Cancer Biology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Kyungmin Ji
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Seema Shah
- Program in Cancer Biology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Raymond R Mattingly
- Program in Cancer Biology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Bonnie F Sloane
- Program in Cancer Biology, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
- Department of Pharmacology, Wayne State University, 540 E. Canfield, Detroit, MI, 48201, USA.
| |
Collapse
|
5
|
Abstract
Understanding breast cancer cell proteolysis and migration is crucial for developing novel therapies to prevent local and distant metastases. Human cancer cells utilize many biological functions comparable to those observed during embryogenesis conferring the cancer cells with survival advantages. One such advantage is the ability to secrete proteases into the tumor microenvironment in order to remodel the extracellular matrix to facilitate migration. These proteases degrade the extracellular matrix, which initially functions as a barrier to cancer cell escape from their site of origin. The extracellular matrix also functions as a reservoir for growth factors that can be released by the secreted proteases and thereby further aid tumor growth and progression. Other survival advantages of tumor cells include: the ability to utilize multiple modes of motility, thrive in acidic microenvironments, and the tumor cell's ability to hijack stromal and immune cells to foster their own migration and survival. In order to reduce metastasis, we must focus our efforts on addressing the survival advantages that tumor cells have acquired.
Collapse
Affiliation(s)
- Kingsley O Osuala
- Department of Pharmacology and Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
| | - Kyungmin Ji
- Department of Pharmacology and Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
| | - Raymond R Mattingly
- Department of Pharmacology and Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
| | - Bonnie F Sloane
- Department of Pharmacology and Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
| |
Collapse
|
6
|
Shah S, Brock EJ, Jackson RM, Ji K, Boerner JL, Sloane BF, Mattingly RR. Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 2018; 20:951-963. [PMID: 30144784 PMCID: PMC6106701 DOI: 10.1016/j.neo.2018.07.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Revised: 07/06/2018] [Accepted: 07/12/2018] [Indexed: 01/13/2023] Open
Abstract
Diagnosis of breast ductal carcinoma in situ (DCIS) presents a challenge since we cannot yet distinguish those cases that would remain indolent and not require aggressive treatment from cases that may progress to invasive ductal cancer (IDC). The purpose of this study is to determine the role of Rap1Gap, a GTPase activating protein, in the progression from DCIS to IDC. Immunohistochemistry (IHC) analysis of samples from breast cancer patients shows an increase in Rap1Gap expression in DCIS compared to normal breast tissue and IDCs. In order to study the mechanisms of malignant progression, we employed an in vitro three-dimensional (3D) model that more accurately recapitulates both structural and functional cues of breast tissue. Immunoblotting results show that Rap1Gap levels in MCF10.Ca1D cells (a model of invasive carcinoma) are reduced compared to those in MCF10.DCIS (a model of DCIS). Retroviral silencing of Rap1Gap in MCF10.DCIS cells activated extracellular regulated kinase (ERK) mitogen-activated protein kinase (MAPK), induced extensive cytoskeletal reorganization and acquisition of mesenchymal phenotype, and enhanced invasion. Enforced reexpression of Rap1Gap in MCF10.DCIS-Rap1GapshRNA cells reduced Rap1 activity and reversed the mesenchymal phenotype. Similarly, introduction of dominant negative Rap1A mutant (Rap1A-N17) in DCIS-Rap1Gap shRNA cells caused a reversion to nonmalignant phenotype. Conversely, expression of constitutively active Rap1A mutant (Rap1A-V12) in noninvasive MCF10.DCIS cells led to phenotypic changes that were reminiscent of Rap1Gap knockdown. Thus, reduction of Rap1Gap in DCIS is a potential switch for progression to an invasive phenotype. The Graphical Abstract summarizes these findings.
Collapse
Affiliation(s)
- Seema Shah
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Ethan J Brock
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Ryan M Jackson
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Kyungmin Ji
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Julie L Boerner
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Bonnie F Sloane
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Raymond R Mattingly
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA; Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, USA.
| |
Collapse
|
7
|
Brock EJ, Jackson R, Boerner JL, Li Q, Sloane BF, Mattingly RR. Abstract B14: Sprouty4 regulates the transition to invasive breast ductal carcinoma through ERK/MAPK signaling. Mol Cancer Res 2018. [DOI: 10.1158/1557-3125.advbc17-b14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer is one of the most common oncologic developments in U.S. women, with approximately 25% of these cases being in situ disease (DCIS). For many years DCIS lesions have been treated using surgery and radiotherapy with the goal of decreasing the amount of late-stage disease. Unfortunately, a number of reports have since shown that early intervention is not sufficient and have highlighted the likelihood of overtreatment. This is especially true for triple-negative breast cancers, which are more strongly associated with distant recurrence, metastasis, and death compared to other types of invasive breast ductal carcinoma (IDC). These factors have generated a substantial clinical need for reliable biomarkers or molecular determinants to assess disease progression. Sprouty proteins are recognized as important regulators of ERK/MAPK signaling, and have been studied in various cancers. We hypothesize that Sprouty4 is an endogenous inhibitor of ERK/MAPK signaling, and its loss or reduced expression is a mechanism by which DCIS lesions progress toward IDC, including triple-negative disease. Using immunohistochemistry we found that Sprouty4 expression was reduced in IDC patient tissue samples compared to normal or DCIS tissues, and that ERK/MAPK activity had an inverse relationship to Sprouty4 expression. These results correspond with immunoblot data from our 3D culture model of breast cancer progression in which Sprouty4 expression was higher during DCIS than in the IDC stage. Efficient overexpression of Sprouty4 reduced both ERK/MAPK activity as well as the aggressive phenotype of MCF10.CA1d IDC cells. Immunofluorescence experiments revealed data consistent with the relocation of E-cadherin back to the cell surface and the restoration of adherens junctions. To determine whether these effects were due to changes in ERK/MAPK signaling, IDC cells were treated with MEK162, an allosteric MEK inhibitor. Nanomolar concentrations of drug produced the restoration of an epithelial-like phenotype similar to Sprouty4 overexpression. From these data we conclude that Sprouty4 may act to control ERK/MAPK signaling in DCIS, thus limiting the progression of these premalignant breast lesions.
Citation Format: Ethan J. Brock, Ryan Jackson, Julie L. Boerner, Quanwen Li, Bonnie F. Sloane, Raymond R. Mattingly. Sprouty4 regulates the transition to invasive breast ductal carcinoma through ERK/MAPK signaling [abstract]. In: Proceedings of the AACR Special Conference: Advances in Breast Cancer Research; 2017 Oct 7-10; Hollywood, CA. Philadelphia (PA): AACR; Mol Cancer Res 2018;16(8_Suppl):Abstract nr B14.
Collapse
Affiliation(s)
| | - Ryan Jackson
- Wayne State University School of Medicine, Detroit, MI
| | | | - Quanwen Li
- Wayne State University School of Medicine, Detroit, MI
| | | | | |
Collapse
|
8
|
Ji K, Zhao Z, Moin K, Xu Y, Gillies RJ, Mattingly RR, Sloane BF. Abstract 2131: Paracrine cytokine pathways mediate metastasis of breast cancer to lymphatics. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Lymphatics, rather than blood vessels, are the primary route for breast cancer metastasis. The presence of breast cancer cells in regional lymphatics, i.e., lymphatic metastasis, is an important prognostic factor for patients. Delineating molecular mechanisms by which the breast cancer cells migrate toward and infiltrate into lymphatics is crucial to designing new therapies to prevent metastatic dissemination. To study tumor:lymphatic interactions, we are using a three-dimensional (3D) heterotypic co-culture model of human breast cancer cells (hBCCs) grown with human microvascular lymphatic endothelial cells (hLECs) in novel chambers that we designed and fabricated. These chambers support growth of the 3D co-cultures, live-cell confocal imaging in real time and noninvasive collection of conditioned media for secretomic analyses. We use live-cell assays developed in our laboratory for quantitative analysis of temporal and dynamic changes in BCC:LEC interactions in correspondence with changes in their malignant and proteolytic phenotypes. We cultured hLECs in the presence and absence of human MDA-MB-231 (231) triple-negative BCCs in 3D cultures for 4 days. In mono-cultures, the 231 cells grow in clusters that exhibit a stellate morphology and hLECs form branching networks with central nodes. We observed that the volumes of 3D structures formed by LECs and 231 cells were significantly greater in co-cultures than in mono-cultures of either cell type. In addition, 231 cells infiltrate into the LEC networks with the infiltration increasing over the 4-day period as assessed by the degree of overlap between 231 cells and hLECs in 3D reconstructions of the co-cultures. Moreover, soluble factors from LECs increase invasive outgrowths of 231 structures. This was demonstrated in 231 cells grown in media conditioned by LECs and in parallel co-cultures of 231 cells and LECs. The induction of invasiveness by LEC conditioned media is reduced by boiling and repeated freeze/thawing, suggesting that the active factor(s) is a protein. Our preliminary results suggest that LECs secrete soluble factors that may be therapeutic targets for reducing invasion of BCCs into lymphatic networks.
Citation Format: Kyungmin Ji, Zhiguo Zhao, Kamiar Moin, Yong Xu, Robert J. Gillies, Raymond R. Mattingly, Bonnie F. Sloane. Paracrine cytokine pathways mediate metastasis of breast cancer to lymphatics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2131.
Collapse
Affiliation(s)
- Kyungmin Ji
- 1Wayne State University School of Medicine, Detroit, MI
| | - Zhiguo Zhao
- 1Wayne State University School of Medicine, Detroit, MI
| | - Kamiar Moin
- 1Wayne State University School of Medicine, Detroit, MI
| | - Yong Xu
- 1Wayne State University School of Medicine, Detroit, MI
| | | | | | | |
Collapse
|
9
|
Abstract
Methodologies to image and quantify the activity of proteolytic enzymes have been developed in an effort to identify protease-related druggable pathways that are involved in malignant progression of cancer. Our laboratory has pioneered techniques for functional live-cell imaging of protease activity in pathomimetic avatars for breast cancer. We analyze proteolysis in the context of proliferation and formation of structures by tumor cells in 3-D cultures over time (4D). In order to recapitulate the cellular composition and architecture of tumors in the pathomimetic avatars, we include other tumor-associated cells (e.g., fibroblasts, myoepithelial cells, microvascular endothelial cells). We also model noncellular aspects of the tumor microenvironment such as acidic pericellular pH. Use of pathomimetic avatars in concert with various types of imaging probes has allowed us to image, quantify, and follow the dynamics of proteolysis in the tumor microenvironment and to test interventions that impact directly or indirectly on proteolytic pathways. To facilitate use of the pathomimetic avatars for screening of therapeutic modalities, we have designed and fabricated custom 3D culture chambers with multiple wells that are either individual or connected by a channel to allow cells to migrate between wells. Optical glass microscope slides underneath an acrylic plate allow the cultures to be imaged with an inverted microscope. Fluid ports in the acrylic plate are at a level above the 3D cultures to allow introduction of culture media and test agents such as drugs into the wells and the harvesting of media conditioned by the cultures for immunochemical and biochemical analyses. We are using the pathomimetic avatars to identify druggable pathways, screen drug and natural product libraries and accelerate entry of validated drugs or natural products into clinical trials.
Collapse
Affiliation(s)
- Anita Chalasani
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, 48201, USA
| | - Kyungmin Ji
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, 48201, USA
| | - Mansoureh Sameni
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, 48201, USA
| | - Samia H Mazumder
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, 48201, USA
| | - Yong Xu
- Department of Electrical and Computer Engineering, Wayne State University, Detroit, MI, 48202, USA
| | - Kamiar Moin
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, 48201, USA
| | - Bonnie F Sloane
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, 48201, USA.
| |
Collapse
|
10
|
Duivenvoorden HM, Rautela J, Edgington‐Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O'Toole SA, Parker BS. Myoepithelial cell‐specific expression of stefin A as a suppressor of early breast cancer invasion. J Pathol 2017; 243:496-509. [DOI: 10.1002/path.4990] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 08/21/2017] [Accepted: 09/18/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Hendrika M Duivenvoorden
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
| | - Jai Rautela
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
- Sir Peter MacCallum Department of Oncology University of Melbourne VIC Australia
- The Walter and Eliza Hall Institute of Medical Research Melbourne VIC Australia
- Department of Medical Biology University of Melbourne VIC Australia
| | - Laura E Edgington‐Mitchell
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences Monash University Melbourne VIC Australia
| | - Alex Spurling
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
| | - David W Greening
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
| | - Cameron J Nowell
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences Monash University Melbourne VIC Australia
| | | | - Elizabeth Robbins
- Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital Camperdown NSW Australia
| | - Natasha K Brockwell
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
| | - Cheok Soon Lee
- Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital Camperdown NSW Australia
- Sydney Medical School University of Sydney NSW Australia
- Cancer Pathology and Cell Biology Laboratory Ingham Institute for Applied Medical Research, and University of New South Wales NSW Australia
- Cancer Pathology, Bosch Institute University of Sydney NSW Australia
| | - Maoshan Chen
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
| | - Anne Holliday
- Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital Camperdown NSW Australia
| | - Cristina I Selinger
- Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital Camperdown NSW Australia
| | - Min Hu
- Department of Medical Oncology Dana‐Farber Cancer Institute, Harvard Medical School Boston Massachusetts USA
| | - Kara L Britt
- Peter MacCallum Cancer Centre Melbourne VIC Australia
| | - David A Stroud
- Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute Monash University Melbourne VIC Australia
| | - Matthew Bogyo
- Department of Pathology Stanford University School of Medicine California USA
| | - Andreas Möller
- Immunology Department QIMR Berghofer Medical Research Institute Brisbane QLD Australia
| | - Kornelia Polyak
- Department of Medical Oncology Dana‐Farber Cancer Institute, Harvard Medical School Boston Massachusetts USA
| | - Bonnie F Sloane
- Department of Pharmacology Wayne State University School of Medicine Detroit Michigan USA
- Barbara Ann Karmanos Cancer Institute Wayne State University School of Medicine Detroit Michigan USA
| | - Sandra A O'Toole
- Sydney Medical School University of Sydney NSW Australia
- Garvan Institute of Medical Research Darlinghurst NSW Australia
- Australian Clinical Labs Bella Vista NSW Australia
| | - Belinda S Parker
- Department of Biochemistry and Genetics La Trobe Institute for Molecular Science Melbourne VIC Australia
| |
Collapse
|
11
|
Abstract
In the effort of developing micro-electrochemical sensors, the miniaturization of reference electrodes has been a challenging task. In this paper, a flexible micro reference electrode with an internal electrolyte reservoir is reported. This new device is based on a unique microfabricated parylene tube structure, which is filled with Cl- rich electrolyte, into which a 50 μm diameter silver (Ag) wire covered with a 7.4 μm thick silver chloride (AgCl) layer is inserted. The distal end of the tube is filled with potassium chloride (KCl) saturated agarose gel. The Ag wire, thick AgCl layer, and internal electrolyte reservoir lead to a long operation time and a stable reference voltage. The drift over a 10-hour period has been found to be less than 2 mV. The total operation time of the device has exceeded 100 hours. Furthermore, the compatibility with microfabrication allows the integration of other components, leading to truly miniaturized electrochemical sensors or sensing systems. To prove this, we demonstrated a pH sensor by combining the reference electrode and an iridium oxide electrode monolithically integrated on the surface of the parylene tube.
Collapse
Affiliation(s)
- Zhiguo Zhao
- Department of Electrical & Computer Engineering, Wayne State University, Detroit, Michigan, USA
- Corresponding Author: Yong Xu, Room 3131 Engineering Building, 5050 Anthony Wayne Dr. Detroit, MI 48202 USA, Phone: 313-577-3850,
| | - Hongen Tu
- Department of Electrical & Computer Engineering, Wayne State University, Detroit, Michigan, USA
- Corresponding Author: Yong Xu, Room 3131 Engineering Building, 5050 Anthony Wayne Dr. Detroit, MI 48202 USA, Phone: 313-577-3850,
| | - Eric GR Kim
- Department of Electrical & Computer Engineering, Wayne State University, Detroit, Michigan, USA
- Department of Biomedical Engineering, Wayne State University, Detroit, Michigan, USA
| | - Bonnie F Sloane
- Department of Pharmacology, Wayne State University, Detroit, Michigan, USA
| | - Yong Xu
- Department of Electrical & Computer Engineering, Wayne State University, Detroit, Michigan, USA
| |
Collapse
|
12
|
Sameni M, Cavallo-Medved D, Franco OE, Chalasani A, Ji K, Aggarwal N, Anbalagan A, Chen X, Mattingly RR, Hayward SW, Sloane BF. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Res 2017; 19:56. [PMID: 28506312 PMCID: PMC5433063 DOI: 10.1186/s13058-017-0847-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Accepted: 04/25/2017] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The breast tumor microenvironment regulates progression of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). However, it is unclear how interactions between breast epithelial and stromal cells can drive this progression and whether there are reliable microenvironmental biomarkers to predict transition of DCIS to IDC. METHODS We used xenograft mouse models and a 3D pathomimetic model termed mammary architecture and microenvironment engineering (MAME) to study the interplay between human breast myoepithelial cells (MEPs) and cancer-associated fibroblasts (CAFs) on DCIS progression. RESULTS Our results show that MEPs suppress tumor formation by DCIS cells in vivo even in the presence of CAFs. In the in vitro MAME model, MEPs reduce the size of 3D DCIS structures and their degradation of extracellular matrix. We further show that the tumor-suppressive effects of MEPs on DCIS are linked to inhibition of urokinase plasminogen activator (uPA)/urokinase plasminogen activator receptor (uPAR)-mediated proteolysis by plasminogen activator inhibitor 1 (PAI-1) and that they can lessen the tumor-promoting effects of CAFs by attenuating interleukin 6 (IL-6) signaling pathways. CONCLUSIONS Our studies using MAME are, to our knowledge, the first to demonstrate a divergent interplay between MEPs and CAFs within the DCIS tumor microenvironment. We show that the tumor-suppressive actions of MEPs are mediated by PAI-1, uPA and its receptor, uPAR, and are sustained even in the presence of the CAFs, which themselves enhance DCIS tumorigenesis via IL-6 signaling. Identifying tumor microenvironmental regulators of DCIS progression will be critical for defining a robust and predictive molecular signature for clinical use.
Collapse
Affiliation(s)
- Mansoureh Sameni
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| | - Dora Cavallo-Medved
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 USA
- Department of Biological Sciences, University of Windsor, Windsor, ON N9B 3P4 Canada
| | - Omar E. Franco
- Department of Surgery, NorthShore University HealthSystem Research Institute, Evanston, IL 60201 USA
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232 USA
| | - Anita Chalasani
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| | - Kyungmin Ji
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| | - Neha Aggarwal
- Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| | - Arulselvi Anbalagan
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| | - Xuequn Chen
- Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| | - Raymond R. Mattingly
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 USA
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| | - Simon W. Hayward
- Department of Surgery, NorthShore University HealthSystem Research Institute, Evanston, IL 60201 USA
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232 USA
- Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232 USA
| | - Bonnie F. Sloane
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201 USA
- Department of Biological Sciences, University of Windsor, Windsor, ON N9B 3P4 Canada
- Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201 USA
| |
Collapse
|
13
|
Jackson RM, Brock EJ, Shah S, Sameni M, Sloane BF, Li Q, Mattingly RR. Abstract B28: Induced expression of Sprouty4 in breast invasive ductal carcinoma cells inhibits ERK MAP kinase and reduces malignant phenotype. Clin Cancer Res 2017. [DOI: 10.1158/1557-3265.pmccavuln16-b28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Our previous work has identified increased expression of Sprouty4 in 3D models of breast ductal carcinoma in situ (DCIS). Sprouty4 in other systems has been shown to function as a negative regulator of the mitogen activated protein kinase (MAPK/ERK) pathway. We hypothesize that Sprouty4 is an endogenous inhibitor of ERK/MAPK signaling in DCIS, and that its loss or reduced expression is one mechanism by which triple-negative lesions progress toward invasive ductal carcinoma (IDC). Using immunohistochemistry our labs have found that Sprouty4 was highly expressed in some human premalignant breast tissue samples, and that this expression was reduced in malignant triple-negative samples. These results correspond with immunoblot data from our 3D culture model of breast cancer progression in which Sprouty4 expression was higher during DCIS than in the IDC stage. Efficient over-expression of Sprouty4 reduced both MAPK/ERK activity as well as the aggressive phenotype of MCF10.CA1d IDC cells. Immunofluorescence experiments done in IDC cells overexpressing Sprouty4 revealed relocation of E-cadherin back to the cell surface and the restoration of adherens junctions. To determine if these effects were due to changes in MAPK/ERK signaling, IDC cells were treated with MEK162, an allosteric MEK inhibitor. Nanomolar concentrations of drug restored an epithelial-like phenotype similar to that produced by Sprouty4 over-expression. From these data we conclude that Sprouty4 may act to control MAPK/ERK signaling in a subset of DCIS, thus limiting the progression of these premalignant breast cancers. Further, if in vivo data correspond with our in vitro work, this may argue for the investigation of MEK inhibitors as an adjunct treatment in triple-negative disease, where options are limited.
Citation Format: Ryan M. Jackson, Ethan J. Brock, Seema Shah, Mansoureh Sameni, Bonnie F. Sloane, Quanwen Li, Raymond R. Mattingly. Induced expression of Sprouty4 in breast invasive ductal carcinoma cells inhibits ERK MAP kinase and reduces malignant phenotype. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B28.
Collapse
|
14
|
Brock EJ, Jackson R, Shah S, Li Q, Sameni M, Krawetz SA, Mao S, Sloane BF, Mattingly RR. Abstract 4560: Induced Sprouty4 expression in breast invasive ductal carcinoma cells downregulates ERK/MAPK activity and restores an epithelial-like phenotype. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer is one of the most common cancers in U.S. women, with approximately 25% of these cases being in situ disease. Sprouty proteins are currently recognized as important regulators of ERK/MAPK signaling, and have been studied in various cancer types. By employing RNA-seq, previous studies from our laboratories determined specific gene expression changes common to three models of ductal carcinoma in situ (DCIS)—MCF10.DCIS, SUM 102, and SUM 225—when compared to MCF10A cells (a model of non-transformed breast epithelium). All cell lines were grown in three-dimensional (3D) reconstituted basement membrane overlay culture because research has shown that the behavior of cancer cells in 3D matrices is more reflective of an in vivo response when exposed to drugs and radiotherapy than if they are cultured on plastic. Among the three models of DCIS, 63 genes were consistently upregulated. We identified 244 promoters associated with these 63 genes and performed bioinformatic data mining that revealed a high level of enrichment for a promoter framework shared by three of these genes: one of which encoded for the protein Sprouty4. We hypothesize that Sprouty4 is an endogenous inhibitor of ERK/MAPK signaling in DCIS, and its loss or reduced expression is a mechanism by which triple-negative lesions progress toward invasive ductal carcinoma (IDC). Using immunohistochemistry we found that Sprouty4 was highly expressed in certain human premalignant breast tissue samples, and that this expression was reduced in malignant triple-negative samples. These results correspond with immunoblot data from our 3D culture model of breast cancer progression in which Sprouty4 expression was higher during DCIS than in the IDC stage. Efficient over-expression of Sprouty4 reduced both ERK/MAPK activity as well as the aggressive phenotype of MCF10.CA1d IDC cells. Immunofluorescence experiments revealed data consistent with the relocation of E-cadherin back to the cell surface and the restoration of adherens. To determine if these effects were due to changes in ERK/MAPK signaling IDC cells were treated with MEK162, an allosteric MEK inhibitor. Nanomolar concentrations of drug produced a restoration of an epithelial-like phenotype similar to Sprouty4 over-expression. From these data we conclude that Sprouty4 may act to control ERK/MAPK signaling in a subset of DCIS, thus limiting the progression of these premalignant breast cancers.
Citation Format: Ethan J. Brock, Ryan Jackson, Seema Shah, Quanwen Li, Mansoureh Sameni, Stephen A. Krawetz, Shihong Mao, Bonnie F. Sloane, Raymond R. Mattingly. Induced Sprouty4 expression in breast invasive ductal carcinoma cells downregulates ERK/MAPK activity and restores an epithelial-like phenotype. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4560.
Collapse
|
15
|
F. Sloane B. Meet Our Editorial Board Member. Curr Protein Pept Sci 2016. [DOI: 10.2174/138920371705160715215814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
16
|
F. Sloane B. Meet Our Editorial Board Member. Curr Protein Pept Sci 2016. [DOI: 10.2174/138920371702160209162928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
17
|
Tovar EA, Sameni M, Essenburg CJ, Chalasani A, Linklater ES, Cherba DM, Anbalagan A, Winn ME, Sloane BF, Graveel CR. Abstract B19: MET and IL6 signaling in triple-negative breast cancer. Mol Cancer Res 2016. [DOI: 10.1158/1557-3125.advbc15-b19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple-negative breast cancer (TNBC) accounts for 15-20% of breast cancers and is associated with advanced stage at diagnosis and poorer outcome compared to other breast cancer subtypes. There is an unmet need for targeted therapeutic strategies for TNBC patients since current treatment options are restricted to standard chemotherapy. Both receptor tyrosine kinase (RTK) and inflammatory signaling have been shown to promote cancer progression and are promising therapeutic targets. Our laboratory was the first to demonstrate that the MET receptor tyrosine kinase is highly expressed in TNBC. Hepatocyte growth factor (HGF), the MET ligand, is highly expressed in breast carcinoma and breast carcinoma-associated fibroblasts (CAFs) and is able to induce paracrine or autocrine MET signaling. MET/HGF signaling is also connected with the pro-inflammatory cytokine interleukin 6 (IL6). HGF and IL6 have been shown to interact to enhance invasion of lung cancer cells and progression of multiple myeloma. In breast cancer patients, high serum expression of HGF and IL6 distinguishes metastatic breast cancers. Nonetheless, there is a gap in knowledge as to whether MET and IL6 signaling pathways directly or indirectly interact and how MET/IL6 activation promotes TNBC progression.
We are examining the novel concept that MET and IL6 signaling pathways act through a positive signaling feedback loop to drive TNBC progression. By understanding the interactions between these signaling networks, we will be able to design therapeutic strategies that target critical signaling nodes in TNBC. Analysis of gene expression profiles in the four molecular TNBC subtypes defined by Burstein et al. revealed that MET, HGF, and IL6 are expressed in each of the TNBC subtypes. Immunohistochemical analysis of HGF and IL6 expression in breast cancer tissues revealed significantly higher HGF and IL6 expression in TNBC compared to ER+ breast cancers. To determine the effect of MET and IL6 inhibition, we established Mammary Architecture and Microenvironment Engineering (MAME) 3D co-culture models of TNBC cells ± fibroblasts. In these models, TNBC cells have high MET expression, moderate to high IL6 expression, and minimal IL6 receptor (IL6R) expression; whereas the CAF cells have high HGF expression and moderate IL6R expression. Our preliminary studies revealed that an IL6 neutralizing antibody (siltuximab) reduced TNBC structure volumes relative to IL6 expression in the TNBC cells, whereas an IL6 receptor (IL6R) neutralizing antibody (tocilizumab) had no effect. These results correlate with IL6 and IL6R expression levels in TNBC cell lines. We evaluated the efficacy of MET inhibition using XL184 (cabozantinib) and observed that XL184 significantly inhibited TNBC growth, proliferation, and invasion of diverse TNBC cell lines, yet was ineffective against MET-negative breast cancer cells. We are currently evaluating the effect of HGF-mediated MET activation on IL6 signaling and inhibition in our 3D TNBC models.
To evaluate the effect of MET and/or IL6 inhibition in vivo we utilized a novel xenograft mouse model that expresses human HGF (hHGFtg SCID). In TNBC cell lines MDA-MB-231 and HCC70, IL6R inhibition slowed tumor progression marginally, whereas MET inhibition with XL184 and the combination of XL184 + anti-IL6R drastically inhibited tumor growth. In a model of established tumor growth, we started treatment when tumor reached 500 mm3. Again we observed a significant decrease in tumor growth with XL184 treatment (p<0.005), but also observed a decrease in tumor growth with anti-IL6R treatment (p<0.03). In our current studies we are evaluating the effects of XL184 and siltuximab treatment in TNBC + CAF tumors. These studies will identify the RTK and inflammatory signaling networks that are critical for TNBC progression and are potential targets for combination therapy.
Citation Format: Elizabeth A. Tovar, Mansoureh Sameni, Curt J. Essenburg, Anita Chalasani, Erik S. Linklater, David M. Cherba, Aruselvi Anbalagan, Mary E. Winn, Bonnie F. Sloane, Carrie R. Graveel. MET and IL6 signaling in triple-negative breast cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Breast Cancer Research; Oct 17-20, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(2_Suppl):Abstract nr B19.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Mary E. Winn
- 1Van Andel Research Institute, Grand Rapids, MI,
| | | | | |
Collapse
|
18
|
Ji K, Zhao Z, Moin K, Xu Y, Sloane BF. Abstract B65: Live-cell imaging of 3D/4D parallel co-cultures of breast carcinoma cells and breast fibroblasts in tissue architecture and microenvironment engineering (TAME) chambers. Mol Cancer Res 2016. [DOI: 10.1158/1557-3125.advbc15-b65] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Interactions among breast carcinoma cells and other cells in the tumor microenvironment, e.g., stromal fibroblasts and immune cells, contribute to malignant progression. We have developed three dimensional (3D) co-culture models and live-cell imaging assays for the analysis of such interactions in real-time, focusing on interactions and associated signaling pathways that might be druggable. Bissell, Brugge and colleagues have elegantly shown that the 3D context of breast cells is essential for their development and neoplastic progression, and the genes down-regulated during acini development in 3D culture are prognostic for clinical outcome of estrogen receptor (ER)-positive and ER-negative breast tumors. We as well as others have demonstrated that 3D cultures of tumor cells can better predict resistance to cytotoxic therapy than 2D monolayer cultures and can be used to identify targets and validate potential therapeutic agents. Nonetheless, in vitro models using only one cell type are at best only partially predictive of in vivo conditions and thus may not be optimal screening platforms for pre-clinical drug discovery. To this end, we have been developing complex 3D co-culture models. We have optimized models that recapitulate in 3D the architecture of the human breast during the transition from normal breast epithelium through pre-malignancy to malignancy and have named them MAME models for mammary architecture and microenvironment engineering models. We have used these models in our laboratory for live-cell imaging and molecular, biochemical and immunochemical analyses in real-time, i.e., 4D (3D + time) of breast tumor cells interacting with other cell types (fibroblasts, myoepithelial cells, lymphatic and blood vessel microvascular endothelial cells, macrophages) in the breast tumor microenvironment. We also developed a live-cell proteolysis assay that allows us to localize and quantify proteolysis and how that is altered by therapeutic approaches and microenvironmental conditions associated with tumors such as acidosis and hypoxia. The MAME models are state-of-the-art in that they allow the analysis of dynamic and temporal processes in live cells and furthermore can be created with all human cells. Thus MAME models provide an alternative to 2D cultures of cancer cells, xenografts of human cancers in mice or transgenic mouse models.
Here we report the development and testing of novel modular chambers designed to allow 3D culture of cancer cells alone or in co-culture (direct and parallel) with other cells over extended periods of time (4D). Because the chambers can be used for cells other than breast, we have designated them tissue architecture and microenvironment engineering (TAME) chambers. With TAME chambers, we have grown for periods ≥60 days human triple negative breast cancer cells, MDA-MB-231, and human breast fibroblasts [normal fibroblasts (NAF98i) and carcinoma-associated fibroblasts (CAF49TKi)]. TAME chambers facilitate collection of conditioned media, without disturbing the cultures, for analyses of dynamic and temporal effects on the secretome; monitoring and quantification by live-cell imaging of dynamic and temporal changes in proliferation, viability, migration, proteolysis and phenotype; regulated introduction of blocking antibodies to cytokines and their receptors; etc. We suggest that TAME chambers will be suitable for high-content imaging and therefore for screening of therapeutic approaches for cancer treatment.
Citation Format: Kyungmin Ji, Zhiguo Zhao, Kamiar Moin, Yong Xu, Bonnie F. Sloane. Live-cell imaging of 3D/4D parallel co-cultures of breast carcinoma cells and breast fibroblasts in tissue architecture and microenvironment engineering (TAME) chambers. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Breast Cancer Research; Oct 17-20, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(2_Suppl):Abstract nr B65.
Collapse
Affiliation(s)
| | | | | | - Yong Xu
- Wayne State University, Detroit, MI
| | | |
Collapse
|
19
|
Weber E, Barbulescu E, Medek R, Reinheckel T, Sameni M, Anbalagan A, Moin K, Sloane BF. Cathepsin B-deficient mice as source of monoclonal anti-cathepsin B antibodies. Biol Chem 2015; 396:277-81. [PMID: 25205719 DOI: 10.1515/hsz-2014-0191] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Accepted: 07/16/2014] [Indexed: 01/18/2023]
Abstract
Cathepsin B has been demonstrated to be involved in several proteolytic processes that support tumor progression and metastasis and neurodegeneration. To further clarify its role, defined monoclonal antibodies are needed. As the primary structure of human cathepsin B is almost identical to that of the mouse, cathepsin B-deficient mice were used in a novel approach for generating such antibodies, providing the chance of an increased immune response to the antigen, human cathepsin B. Thirty clones were found to produce cathepsin B-specific antibodies. Seven of these antibodies were used to detect cathepsin B in MCF10-DCIS human breast cancer cells by immunocytochemistry and immunoblotting. Five different binding sites were identified by epitope mapping giving the opportunity to combine these antibodies in oligoclonal antibody mixtures for an improved detection of cathepsin B.
Collapse
|
20
|
Ramalho SD, Sharma R, White JK, Aggarwal N, Chalasani A, Sameni M, Moin K, Vieira PC, Turro C, Kodanko JJ, Sloane BF. Imaging Sites of Inhibition of Proteolysis in Pathomimetic Human Breast Cancer Cultures by Light-Activated Ruthenium Compound. PLoS One 2015; 10:e0142527. [PMID: 26562785 PMCID: PMC4643019 DOI: 10.1371/journal.pone.0142527] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 10/22/2015] [Indexed: 11/21/2022] Open
Abstract
The cysteine protease cathepsin B has been causally linked to progression and metastasis of breast cancers. We demonstrate inhibition by a dipeptidyl nitrile inhibitor (compound 1) of cathepsin B activity and also of pericellular degradation of dye-quenched collagen IV by living breast cancer cells. To image, localize and quantify collagen IV degradation in real-time we used 3D pathomimetic breast cancer models designed to mimic the in vivo microenvironment of breast cancers. We further report the synthesis and characterization of a caged version of compound 1, [Ru(bpy)2(1)2](BF4)2 (compound 2), which can be photoactivated with visible light. Upon light activation, compound 2, like compound 1, inhibited cathepsin B activity and pericellular collagen IV degradation by the 3D pathomimetic models of living breast cancer cells, without causing toxicity. We suggest that caged inhibitor 2 is a prototype for cathepsin B inhibitors that can control both the site and timing of inhibition in cancer.
Collapse
Affiliation(s)
- Suelem D. Ramalho
- Department of Chemistry, Federal University of São Carlos, São Carlos, São Paulo, Brazil
| | - Rajgopal Sharma
- Department of Chemistry, Wayne State University, Detroit, Michigan, United States of America
| | - Jessica K. White
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio, United States of America
| | - Neha Aggarwal
- Department of Physiology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America
| | - Anita Chalasani
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America
| | - Mansoureh Sameni
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America
| | - Kamiar Moin
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America
- Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America
| | - Paulo C. Vieira
- Department of Chemistry, Federal University of São Carlos, São Carlos, São Paulo, Brazil
| | - Claudia Turro
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio, United States of America
| | - Jeremy J. Kodanko
- Department of Chemistry, Wayne State University, Detroit, Michigan, United States of America
- * E-mail: (BFS); (JJK)
| | - Bonnie F. Sloane
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America
- Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan, United States of America
- * E-mail: (BFS); (JJK)
| |
Collapse
|
21
|
Aggarwal N, Santiago AM, Kessel D, Sloane BF. Photodynamic therapy as an effective therapeutic approach in MAME models of inflammatory breast cancer. Breast Cancer Res Treat 2015; 154:251-62. [PMID: 26502410 DOI: 10.1007/s10549-015-3618-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Accepted: 10/20/2015] [Indexed: 12/18/2022]
Abstract
Photodynamic therapy (PDT) is a minimally invasive, FDA-approved therapy for treatment of endobronchial and esophageal cancers that are accessible to light. Inflammatory breast cancer (IBC) is an aggressive and highly metastatic form of breast cancer that spreads to dermal lymphatics, a site that would be accessible to light. IBC patients have a relatively poor survival rate due to lack of targeted therapies. The use of PDT is underexplored for breast cancers but has been proposed for treatment of subtypes for which a targeted therapy is unavailable. We optimized and used a 3D mammary architecture and microenvironment engineering (MAME) model of IBC to examine the effects of PDT using two treatment protocols. The first protocol used benzoporphyrin derivative monoacid A (BPD) activated at doses ranging from 45 to 540 mJ/cm(2). The second PDT protocol used two photosensitizers: mono-L-aspartyl chlorin e6 (NPe6) and BPD that were sequentially activated. Photokilling by PDT was assessed by live-dead assays. Using a MAME model of IBC, we have shown a significant dose-response in photokilling by BPD-PDT. Sequential activation of NPe6 followed by BPD is more effective in photokilling of tumor cells than BPD alone. Sequential activation at light doses of 45 mJ/cm(2) for each agent resulted in >90 % cell death, a response only achieved by BPD-PDT at a dose of 360 mJ/cm(2). Our data also show that effects of PDT on a volumetric measurement of 3D MAME structures reflect efficacy of PDT treatment. Our study is the first to demonstrate the potential of PDT for treating IBC.
Collapse
Affiliation(s)
- Neha Aggarwal
- Department of Physiology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Ann Marie Santiago
- Department of Pharmacology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI, 48201, USA.
| | - David Kessel
- Department of Pharmacology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Bonnie F Sloane
- Department of Pharmacology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI, 48201, USA.
- Department of Oncology, Wayne State University School of Medicine, 540 East Canfield, Detroit, MI, 48201, USA.
| |
Collapse
|
22
|
Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR, Sloane BF. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models. Clin Cancer Res 2015; 22:923-34. [PMID: 26432786 DOI: 10.1158/1078-0432.ccr-15-0187] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Accepted: 09/20/2015] [Indexed: 12/31/2022]
Abstract
PURPOSE Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is associated with poor clinical outcome. There is a vital need for effective targeted therapeutics for TNBC patients, yet treatment strategies are challenged by the significant intertumoral heterogeneity within the TNBC subtype and its surrounding microenvironment. Receptor tyrosine kinases (RTK) are highly expressed in several TNBC subtypes and are promising therapeutic targets. In this study, we targeted the MET receptor, which is highly expressed across several TNBC subtypes. EXPERIMENTAL DESIGN Using the small-molecule inhibitor cabozantinib (XL184), we examined the efficacy of MET inhibition in preclinical models that recapitulate human TNBC and its microenvironment. To analyze the dynamic interactions between TNBC cells and fibroblasts over time, we utilized a 3D model referred to as MAME (Mammary Architecture and Microenvironment Engineering) with quantitative image analysis. To investigate cabozantinib inhibition in vivo, we used a novel xenograft model that expresses human HGF and supports paracrine MET signaling. RESULTS XL184 treatment of MAME cultures of MDA-MB-231 and HCC70 cells (± HGF-expressing fibroblasts) was cytotoxic and significantly reduced multicellular invasive outgrowths, even in cultures with HGF-expressing fibroblasts. Treatment with XL184 had no significant effects on MET(neg) breast cancer cell growth. In vivo assays demonstrated that cabozantinib treatment significantly inhibited TNBC growth and metastasis. CONCLUSIONS Using preclinical TNBC models that recapitulate the breast tumor microenvironment, we demonstrate that cabozantinib inhibition is an effective therapeutic strategy in several TNBC subtypes.
Collapse
Affiliation(s)
- Mansoureh Sameni
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan
| | - Elizabeth A Tovar
- Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan
| | - Curt J Essenburg
- Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan
| | - Anita Chalasani
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan
| | - Erik S Linklater
- Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan
| | - Andrew Borgman
- Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, Michigan
| | - David M Cherba
- Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, Michigan
| | - Arulselvi Anbalagan
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan
| | - Mary E Winn
- Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, Michigan
| | - Carrie R Graveel
- Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan.
| | - Bonnie F Sloane
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan. Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
| |
Collapse
|
23
|
Abstract
Proteases are essential for normal physiology as well as multiple diseases, e.g., playing a causative role in cancer progression, including in tumor angiogenesis, invasion, and metastasis. Identification of dynamic alterations in protease activity may allow us to detect early stage cancers and to assess the efficacy of anti-cancer therapies. Despite the clinical importance of proteases in cancer progression, their functional roles individually and within the context of complex protease networks have not yet been well defined. These gaps in our understanding might be addressed with: 1) accurate and sensitive tools and methods to directly identify changes in protease activities in live cells, and 2) pathomimetic avatars for cancer that recapitulate in vitro the tumor in the context of its cellular and non-cellular microenvironment. Such avatars should be designed to facilitate mechanistic studies that can be translated to animal models and ultimately the clinic. Here, we will describe basic principles and recent applications of live-cell imaging for identification of active proteases. The avatars optimized by our laboratory are three-dimensional (3D) human breast cancer models in a matrix of reconstituted basement membrane (rBM). They are designated mammary architecture and microenvironment engineering (MAME) models as they have been designed to mimic the structural and functional interactions among cell types in the normal and cancerous human breast. We have demonstrated the usefulness of these pathomimetic avatars for following dynamic and temporal changes in cell:cell interactions and quantifying changes in protease activity associated with these interactions in real-time (4D). We also briefly describe adaptation of the avatars to custom-designed and fabricated tissue architecture and microenvironment engineering (TAME) chambers that enhance our ability to analyze concomitant changes in the malignant phenotype and the associated tumor microenvironment.
Collapse
Affiliation(s)
- Kyungmin Ji
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Joshua Heyza
- Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI 48201, USA; Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Dora Cavallo-Medved
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201, USA; Department of Biological Sciences, University of Windsor, Windsor, Canada.
| | - Bonnie F Sloane
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201, USA; Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI 48201, USA; Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA; Department of Biological Sciences, University of Windsor, Windsor, Canada.
| |
Collapse
|
24
|
Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer 2015; 15:584. [PMID: 26268945 PMCID: PMC4535667 DOI: 10.1186/s12885-015-1576-3] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 07/27/2015] [Indexed: 12/14/2022] Open
Abstract
Background Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive breast cancer in which approximately half the patients will progress to invasive cancer. Gaining a better understanding of DCIS progression may reduce overtreatment of patients. Expression of the pro-inflammatory cytokine interleukin-6 increases with pathological stage and grade, and is associated with poorer prognosis in breast cancer patients. Carcinoma associated fibroblasts (CAFs), which are present in the stroma of DCIS patients are known to secrete pro-inflammatory cytokines and promote tumor progression. Methods We hypothesized that IL-6 paracrine signaling between DCIS cells and CAFs mediates DCIS proliferation and migration. To test this hypothesis, we utilized the mammary architecture and microenvironment engineering or MAME model to study the interactions between human breast CAFs and human DCIS cells in 3D over time. We specifically inhibited autocrine and paracrine IL-6 signaling to determine its contribution to early stage tumor progression. Results Here, DCIS cells formed multicellular structures that exhibited increased proliferation and migration when cultured with CAFs. Treatment with an IL-6 neutralizing antibody inhibited growth and migration of the multicellular structures. Moreover, selective knockdown of IL-6 in CAFs, but not in DCIS cells, abrogated the migratory phenotype. Conclusion Our results suggest that paracrine IL-6 signaling between preinvasive DCIS cells and stromal CAFs represent an important factor in the initiation of DCIS progression to invasive breast carcinoma. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1576-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Kingsley O Osuala
- Department of Pharmacology, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA. .,School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Mansoureh Sameni
- Department of Pharmacology, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA. .,School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Seema Shah
- Cancer Biology Program, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA. .,School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Neha Aggarwal
- Department of Physiology, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA. .,School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Michelle L Simonait
- School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Omar E Franco
- Department of Surgery, NorthShore University Health System Research Institute, 1001 University Place, Evanston, IL, 60201, USA.
| | - Yan Hong
- Division of Cancer and Developmental Biology, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
| | - Simon W Hayward
- Department of Surgery, NorthShore University Health System Research Institute, 1001 University Place, Evanston, IL, 60201, USA.
| | - Fariba Behbod
- Division of Cancer and Developmental Biology, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
| | - Raymond R Mattingly
- Department of Pharmacology, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA. .,School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA.
| | - Bonnie F Sloane
- Department of Pharmacology, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA. .,School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI, 48201, USA.
| |
Collapse
|
25
|
Ibrahim SA, Elghonaimy EA, El-Shinawi M, El-Halawany M, Nouh MA, El-Mamlouk T, Sloane BF, Mohamed MM. Abstract 430: MCP-1/CCL2 and IL-8 regulate proteolytic activity of triple negative inflammatory breast cancer via cathepsin B, ERK1/2, JAK1 and Src signaling pathways. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Recently, we have shown that macrophages isolated from the tumor microenvironment of IBC patients secrete monocyte chemoattractant protein-1/CC-chemokine ligand 2 (MCP-1/CCL2) and IL-8 that augment dissemination and metastasis of IB carcinoma cells. However, the precise molecular mechanism by which these cytokines exert their effect is still unclear.
Methods
In the present study, the triple negative breast cancer (TNBC) cell lines Sum149 (IBC) and HCC70 (non-IBC) cells were employed to analyze the effect of IL-8 and MCP-1/CCL2 on the proteolytic activity using live cell imaging assay, expression of cathepsin B and the activation status of STAT3, AKT, JAK1 and Src. In addition, we enrolled TNBC patients sub-grouped into IBC (n = 15), non-IBC (n = 19) patients.
Results
Our results revealed that upon stimulation with MCP-1/CCL2 and IL-8, Sum149 cells and HCC70 exhibited an increase in DQ-collagen degradation-mediated proteolytic activity. Mechanistically, MCP-1/CCL2 and IL-8 increase collagen degradation via enhanced expression of cathepsin B single chain mature enzyme (31 kDa) and the heavy chain of double chain mature enzyme (25/26 kDa). Moreover, MCP-1/CCL2 and IL-8 enhance activation of STAT3, ERK1/2 and AKT in both Sum149 and HCC70 cells. Interestingly, we detected over-expression of cathepsin B in the carcinoma tissues of TNBC-IBC patients compared to non-IBC patients. Over expression of cathepsin B found to be associated with activation of Src and ERK1/2, in IBC as compared to non-IBC tissues.
Conclusions
Our data indicate that MCP-1/CCL2 and IL-8 stimulate proteolytic activity, cathepsin B expression and Src-ERK1/2 pathway in IBC tissues versus non-IBC. Targeting MCP-1/CCL2 and IL-8 in triple negative IBC patients represents a promising therapeutic strategy.
Citation Format: Sherif A. Ibrahim, Eslam A. Elghonaimy, Mohamed El-Shinawi, Medhat El-Halawany, Mohamed A. Nouh, Tahani El-Mamlouk, Bonnie F. Sloane, Mona Mostafa Mohamed. MCP-1/CCL2 and IL-8 regulate proteolytic activity of triple negative inflammatory breast cancer via cathepsin B, ERK1/2, JAK1 and Src signaling pathways. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 430. doi:10.1158/1538-7445.AM2015-430
Collapse
|
26
|
Tan CD, Hobbs C, Sameni M, Sloane BF, Stutts MJ, Tarran R. Cathepsin B contributes to Na+ hyperabsorption in cystic fibrosis airway epithelial cultures. J Physiol 2014; 592:5251-68. [PMID: 25260629 DOI: 10.1113/jphysiol.2013.267286] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
In cystic fibrosis (CF) lung disease, the absence of functional CF transmembrane conductance regulator results in Cl(-)/HCO3 (-) hyposecretion and triggers Na(+) hyperabsorption through the epithelial Na(+) channel (ENaC), which contribute to reduced airway surface liquid (ASL) pH and volume. Prostasin, a membrane-anchored serine protease with trypsin-like substrate specificity has previously been shown to activate ENaC in CF airways. However, prostasin is typically inactive below pH 7.0, suggesting that it may be less relevant in acidic CF airways. Cathepsin B (CTSB) is present in both normal and CF epithelia and is secreted into ASL, but little is known about its function in the airways. We hypothesized that the acidic ASL seen in CF airways may stimulate CTSB to activate ENaC, contributing to Na(+) hyperabsorption and depletion of CF ASL volume. In Xenopus laevis oocytes, CTSB triggered α- and γENaC cleavage and induced an increase in ENaC activity. In bronchial epithelia from both normal and CF donor lungs, CTSB localized to the apical membrane. In normal and CF human bronchial epithelial cultures, CTSB was detected at the apical plasma membrane and in the ASL. CTSB activity was significantly elevated in acidic ASL, which correlated with increased abundance of ENaC in the plasma membrane and a reduction in ASL volume. This acid/CTSB-dependent activation of ENaC was ameliorated with the cell impermeable, CTSB-selective inhibitor CA074, suggesting that CTSB inhibition may have therapeutic relevance. Taken together, our data suggest that CTSB is a pathophysiologically relevant protease that activates ENaC in CF airways.
Collapse
Affiliation(s)
- Chong Da Tan
- Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC, USA
| | - Carey Hobbs
- Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC, USA
| | - Mansoureh Sameni
- Department of Pharmacology, Wayne State University, School of Medicine, Detroit, MI, USA
| | - Bonnie F Sloane
- Department of Pharmacology, Wayne State University, School of Medicine, Detroit, MI, USA
| | - M Jackson Stutts
- Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC, USA
| | - Robert Tarran
- Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
27
|
Abstract
Proteases, including intracellular proteases, play roles at many different stages of malignant progression. Our focus here is cathepsin B, a lysosomal cysteine cathepsin. High levels of cathepsin B are found in a wide variety of human cancers, levels that often induce secretion and association of cathepsin B with the tumor cell membrane. In experimental models, such as transgenic models of murine pancreatic and mammary carcinomas, causal roles for cathepsin B have been demonstrated in initiation, growth/tumor cell proliferation, angiogenesis, invasion, and metastasis. Tumor growth in transgenic models is promoted by cathepsin B in tumor-associated cells, for example, tumor-associated macrophages, as well as in tumor cells. In transgenic models, the absence of cathepsin B has been associated with enhanced apoptosis, yet cathepsin B also has been shown to contribute to apoptosis. Cathepsin B is part of a proteolytic pathway identified in xenograft models of human glioma; targeting only cathepsin B in these tumors is less effective than targeting cathepsin B in combination with other proteases or protease receptors. Understanding the mechanisms responsible for increased expression of cathepsin B in tumors and association of cathepsin B with tumor cell membranes is needed to determine whether targeting cathepsin B could be of therapeutic benefit.
Collapse
Affiliation(s)
- Neha Aggarwal
- Department of Physiology, Wayne State University School of Medicine, Detroit, Ml, USA
| | - Bonnie F. Sloane
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Ml, USA
| |
Collapse
|
28
|
Osuala KO, Sloane BF. Many Roles of CCL20: Emphasis on Breast Cancer. Postdoc J 2014; 2:7-16. [PMID: 27631019 PMCID: PMC5019369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
CCL20 or MIP3α is a small ~8 kDa protein primarily expressed in the liver, colon, prostate, cervix, and skin. The cellular receptor for CCL20 is CCR6. CCl20 unlike many other cytokines only binds CCR6, making the CCL20/CCR6 pathway an attractive drug target. Since the initial discovery of CCL20 in the early 1990's, there has been an increase in the evidence implicating the chemokine and its receptor in a number of diseases, including rheumatoid arthritis and human immunodeficiency virus infection. CCL20 has also been linked to malignancies such as ovarian, colorectal and pancreatic cancers. CCL20 can also attract tumor-promoting immune-suppressive cells to the tumor microenvironment, which may contribute to the immune evasive potential of the tumor and tumor progression.
Collapse
Affiliation(s)
- Kingsley O. Osuala
- Wayne State University, Department of Pharmacology, School of Medicine, 540 E Canfield,Detroit, MI 48201, USA
| | - Bonnie F. Sloane
- Wayne State University, Department of Pharmacology, School of Medicine, 540 E Canfield,Detroit, MI 48201, USA
| |
Collapse
|
29
|
Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol 2014. [DOI: 10.1016/j.biocel.2013.11.015 s1357-2725(13)00353-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/01/2022]
|
30
|
Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol 2013; 46:138-47. [PMID: 24291763 DOI: 10.1016/j.biocel.2013.11.015] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2013] [Revised: 09/02/2013] [Accepted: 11/05/2013] [Indexed: 12/20/2022]
Abstract
Although there is a growing literature describing the role of macrophages in breast cancer, the role of macrophages in inflammatory breast cancer (IBC) is unclear. The aim of present study was to isolate and characterize tumor associated macrophages of IBC and non-IBC patients and define their role in IBC. Tumor infiltrating monocytes/macrophages (CD14+ and CD68+) were measured by immunohistochemistry using specific monoclonal antibodies. Blood drained from axillary vein tributaries was collected during breast cancer surgery and the percentage of CD14+ in the total isolated leukocytes was assessed by flow cytometric analysis. CD14+ cells were separated from total leukocytes by immuno-magnetic beads technique and were cultured overnight. Media conditioned by CD14+ were collected and subjected to cytokine profiling using cytokine antibody array. Wound healing and invasion assays were used to test whether cytokines highly secreted by tumor drained macrophages induce motility and invasion of breast cancer cells. We found that macrophages highly infiltrate into carcinoma tissues of IBC patients. In addition blood collected from axillary tributaries of IBC patients is highly enriched with CD14+ cells as compared to blood collected from non-IBC patients. Cytokine profiling of CD14+ cells isolated from IBC patients revealed a significant increase in secretion of tumor necrosis factor-α; monocyte chemoattractant protein-1/CC-chemokine ligand 2; interleukin-8 and interleukin-10 as compared to CD14+ cells isolated from non-IBC patients. Tumor necrosis factor-α, interleukin-8 and interleukin-10 significantly increased motility and invasion of IBC cells in vitro. In conclusion, macrophages isolated from the tumor microenvironment of IBC patients secrete chemotactic cytokines that may augment dissemination and metastasis of IBC carcinoma cells.
Collapse
Affiliation(s)
- Mona M Mohamed
- Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
| | - Eslam A El-Ghonaimy
- Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.
| | - Mohamed A Nouh
- Department of Pathology, National Cancer institute, Cairo University, Giza 12613, Egypt.
| | - Robert J Schneider
- Department of Microbiology, New York University, School of Medicine, 10016 New York, USA.
| | - Bonnie F Sloane
- Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
| | - Mohamed El-Shinawi
- Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
| |
Collapse
|
31
|
Mohamed MM, El-Ghonaimy EA, Nouh MA, Schneider RJ, Sloane BF, El-Shinawi M. Abstract B40: Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Cancer Res 2013. [DOI: 10.1158/1538-7445.fbcr13-b40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer and is characterized by rapid progression and dismal outcome. Although there is a growing literature describing the role of macrophages in non-IBC, the role of macrophages in IBC is unclear. The aims of the present study were to: 1) assess macrophages infiltration within the tumor tissues of non-IBC and IBC patients; 2) isolate and profile cytokines of macrophages drained from breast tumor axillary tributaries of non-IBC and IBC patients and 3) test whether major cytokines secreted by tumor draining macrophages induce motility of the IBC cell line SUM149.
Methods: Tumor-infiltrating macrophages were measured by immunohistochemical (IHC) techniques using CD14 and CD68 monoclonal antibodies. Blood drained from axillary vein tributaries was collected from non-IBC and IBC patients during breast cancer surgery and total mononuclear cells isolated by density gradient centrifugation using Histopaque. The percentage of monocytes/macrophages (CD14+) in the total isolated leukocytes was calculated by flow cytometry using fluorochrome-labeled monoclonal antibodies (APC-CD14 and PerCP-CD3). CD14+ population was separated from total mononuclear cells using an immuno-magnetic bead separation technique. CD14+ cells were seeded overnight in appropriate culture media at 37°C in a humidified CO2 incubator and conditioned media were collected and cytokines profiled. To test whether cytokines secreted by CD14+ enhances motility and invasion of SUM149 cells, we used wound healing and invasion assays.
Results: Our results revealed that there was an increase in the number of infiltrated macrophages (CD14+ cells) in IBC tumor tissues and axillary tributaries drained blood as compared to non-IBC. Cytokine profiling of IBC-CD14+ cells revealed a significant increase in tumor necrosis factor-alpha (TNF-α); monocyte chemoattractant protein-1 (MCP-1) also known as CC-chemokine ligand 2 (CCL-2); interleukin-10 (IL-10) and interleukin-8 (IL-8) as compared to non-IBC CD14+ cells. TNF-α, IL-8 and IL-10 cytokines significantly increased motility and invasion of SUM149 cells.
Conclusion: IBC cancer tissues are characterized by high infiltration of monocytes/macrophages that secrete cytokines that may contribute to dissemination of IBC cells.
Citation Format: Mona Mostafa Mohamed, Eslam A. El-Ghonaimy, Mohamed A. Nouh, Robert J. Schneider, Bonnie F. Sloane, Mohamed El-Shinawi. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. [abstract]. In: Proceedings of the Third AACR International Conference on Frontiers in Basic Cancer Research; Sep 18-22, 2013; National Harbor, MD. Philadelphia (PA): AACR; Cancer Res 2013;73(19 Suppl):Abstract nr B40.
Collapse
Affiliation(s)
| | | | - Mohamed A. Nouh
- 2Cairo University, National Cancer Institute, Giza, Egypt, Arab Rep.,
| | | | | | | |
Collapse
|
32
|
Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, Coussens LM. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 2013; 27:2086-98. [PMID: 24065739 PMCID: PMC3850093 DOI: 10.1101/gad.224899.113] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Serine and cysteine cathepsin (Cts) proteases are involved in tumor progression. CtsB plays a significant role during mammary carcinogenesis. Ruffell et al. find that squamous carcinomas develop independently of CtsB. CtsC is not required during mammary carcinogenesis but is necessary for squamous carcinogenesis. Dermal/stromal fibroblasts and bone marrow-derived cells express elevated levels of enzymatically active CtsC that regulate the complexity of infiltrating immune cells in neoplastic skin, development of angiogenic vasculature, and squamous cell carcinoma growth. These findings indicate that tissue specificity can define functional significance. Serine and cysteine cathepsin (Cts) proteases are an important class of intracellular and pericellular enzymes mediating multiple aspects of tumor development. Emblematic of these is CtsB, reported to play functionally significant roles during pancreatic islet and mammary carcinogenesis. CtsC, on the other hand, while up-regulated during pancreatic islet carcinogenesis, lacks functional significance in mediating neoplastic progression in that organ. Given that protein expression and enzymatic activity of both CtsB and CtsC are increased in numerous tumors, we sought to understand how tissue specificity might factor into their functional significance. Thus, whereas others have reported that CtsB regulates metastasis of mammary carcinomas, we found that development of squamous carcinomas occurs independently of CtsB. In contrast to these findings, our studies found no significant role for CtsC during mammary carcinogenesis but revealed squamous carcinogenesis to be functionally dependent on CtsC. In this context, dermal/stromal fibroblasts and bone marrow-derived cells expressed increased levels of enzymatically active CtsC that regulated the complexity of infiltrating immune cells in neoplastic skin, development of angiogenic vasculature, and overt squamous cell carcinoma growth. These studies highlight the important contribution of tissue/microenvironment context to solid tumor development and indicate that tissue specificity defines functional significance for these two members of the cysteine protease family.
Collapse
Affiliation(s)
- Brian Ruffell
- Department of Pathology, University of California at San Francisco, San Francisco, California 94143, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Kaur H, Mao S, Shah S, Gorski DH, Krawetz SA, Sloane BF, Mattingly RR. Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. Expert Rev Mol Diagn 2013; 13:151-65. [PMID: 23477556 DOI: 10.1586/erm.13.4] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Mammographic screening leads to frequent biopsies and concomitant overdiagnosis of breast cancer, particularly ductal carcinoma in situ (DCIS). Some DCIS lesions rapidly progress to invasive carcinoma, whereas others remain indolent. Because we cannot yet predict which lesions will not progress, all DCIS is regarded as malignant, and many women are overtreated. Thus, there is a pressing need for a panel of molecular markers in addition to the current clinical and pathological factors to provide prognostic information. Genomic technologies such as microarrays have made major contributions to defining subtypes of breast cancer. Next-generation sequencing (NGS) modalities offer unprecedented depth of expression analysis through revealing transcriptional boundaries, mutations, rare transcripts and alternative splice variants. NGS approaches are just beginning to be applied to DCIS. Here, the authors review the applications and challenges of NGS in discovering novel potential therapeutic targets and candidate biomarkers in the premalignant progression of breast cancer.
Collapse
Affiliation(s)
- Hitchintan Kaur
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Mullins SR, Sameni M, Blum G, Bogyo M, Sloane BF, Moin K. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem 2013; 393:1405-16. [PMID: 23667900 DOI: 10.1515/hsz-2012-0252] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The expression of the cysteine protease cathepsin B is increased in early stages of human breast cancer.To assess the potential role of cathepsin B in premalignant progression of breast epithelial cells, we employed a 3D reconstituted basement membrane overlay culture model of MCF10A human breast epithelial cells and isogenic variants that replicate the in vivo phenotypes of hyper plasia(MCF10AneoT) and atypical hyperplasia (MCF10AT1). MCF10A cells developed into polarized acinar structures with central lumens. In contrast, MCF10AneoT and MCF10AT1 cells form larger structures in which the lumens are filled with cells. CA074Me, a cell-permeable inhibitor selective for the cysteine cathepsins B and L,reduced proliferation and increased apoptosis of MCF10A, MCF10AneoT and MCF10AT1 cells in 3D culture. We detected active cysteine cathepsins in the isogenic MCF10 variants in 3D culture with GB111, a cell-permeable activity based probe, and established differential inhibition of cathepsin B in our 3D cultures. We conclude that cathepsin B promotes proliferation and premalignant progression of breast epithelial cells. These findings are consistent with studies by others showing that deletion of cathepsin B in the transgenic MMTV-PyMT mice, a murine model that is predisposed to development of mammary cancer, reduces malignant progression.
Collapse
|
35
|
Caglič D, Repnik U, Jedeszko C, Kosec G, Miniejew C, Kindermann M, Vasiljeva O, Turk V, Wendt KU, Sloane BF, Goldring MB, Turk B. The proinflammatory cytokines interleukin-1α and tumor necrosis factor α promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes. Biol Chem 2013; 394:307-16. [DOI: 10.1515/hsz-2012-0283] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Accepted: 10/30/2012] [Indexed: 11/15/2022]
Abstract
Abstract
Osteoarthritis and rheumatoid arthritis are destructive joint diseases that involve the loss of articular cartilage. Degradation of cartilage extracellular matrix is believed to occur due to imbalance between the catabolic and anabolic processes of resident chondrocytes. Previous work has suggested that various lysosomal cysteine cathepsins participate in cartilage degeneration; however, their exact roles in disease development and progression have not been elucidated. In order to study degradation processes under conditions resembling the in vivo milieu of the cartilage, we cultivated chondrocytes on a type II collagen-containing matrix. Stimulation of the cultivated chondrocytes with interleukin-1α and/or tumor necrosis factor α resulted in a time-dependent increase in cathepsin S expression and induced its secretion into the conditioned media. Using a novel bioluminescent activity-based probe, we were able to demonstrate a significant increase in proteolytic activity of cathepsin S in the conditioned media of proinflammatory cytokine-stimulated chondrocytes. For the first time, cathepsin S was demonstrated to be secreted from chondrocytes upon stimulation with the proinflammatory cytokines, and displayed proteolytic activity in culture supernatants. Its stability at neutral pH and potent proteolytic activity on extracellular matrix components mean that cathepsin S may contribute significantly to cartilage degradation and may thus be considered a potential drug target in joint diseases.
Collapse
|
36
|
Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, Johnson J, Gatenby RA, Gillies RJ. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res 2013; 73:1524-35. [PMID: 23288510 DOI: 10.1158/0008-5472.can-12-2796] [Citation(s) in RCA: 874] [Impact Index Per Article: 79.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The pH of solid tumors is acidic due to increased fermentative metabolism and poor perfusion. It has been hypothesized that acid pH promotes local invasive growth and metastasis. The hypothesis that acid mediates invasion proposes that H(+) diffuses from the proximal tumor microenvironment into adjacent normal tissues where it causes tissue remodeling that permits local invasion. In the current work, tumor invasion and peritumoral pH were monitored over time using intravital microscopy. In every case, the peritumoral pH was acidic and heterogeneous and the regions of highest tumor invasion corresponded to areas of lowest pH. Tumor invasion did not occur into regions with normal or near-normal extracellular pH. Immunohistochemical analyses revealed that cells in the invasive edges expressed the glucose transporter-1 and the sodium-hydrogen exchanger-1, both of which were associated with peritumoral acidosis. In support of the functional importance of our findings, oral administration of sodium bicarbonate was sufficient to increase peritumoral pH and inhibit tumor growth and local invasion in a preclinical model, supporting the acid-mediated invasion hypothesis. Cancer Res; 73(5); 1524-35. ©2012 AACR.
Collapse
Affiliation(s)
- Veronica Estrella
- Departments of Cancer Imaging and Metabolism, Radiology, and Analytic Microscopy Laboratory, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
ElGhonaimy EA, El-Shinawi M, Abd-El-Tawab R, El Mamlouk T, Sloane BF, Mohamed MM. Abstract P1-05-11: Biological characterization of tumor-associated leukocytes in positive and negative lymph node breast cancer patients. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-05-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Leukocytes plays crucial role in breast cancer progression and lymph node metastasis. Veins draining the breast through the axillary tributaries contain tumor-associated leukocytes migrating away from tumor microenvironment. Collecting tumor-associated leukocytes and characterizing their immunophenotype and biological properties in positive and negative lymph node patients may elucidate their role in lymph node metastasis.
Aims: Using an innovative surgical approach previously described, wecollectedtumor-associated leukocytes from venous drainage of the breast during breast cancer surgery of positive and negative lymph node (LN)metastasis patients. Isolated leukocytes were subjected to: 1) immunophenotyping; 2) cytokine profiling; and 3) assessment of the expression level of total and phospho NF-kβ.
Material and Methods: We enrolled 40 patients diagnosed with breast cancer from Ain Shams University Hospitals. Patients were sub-grouped into negative (zero) and positive (4) LN metastasis patients. All enrolled patients had not received neo-adjuvant chemotherapy. During modified radical mastectomy or conservative breast surgery, 15–20 ml of blood were collected from axillary vein tributaries for the isolation of tumor-associated leukocytes by Ficoll-Hypaque density gradient centrifugation. The immunophenotype of the isolated mononuclear cells was assessed using flow cytometry to identify the percentage of T lymphocytes (CD3+) and their subpopulations (CD4+ and CD8+), NK cells (CD56+) and B-lymphocytes (CD19+). Tumor-associated leukocytes isolated from positive and negative LN patients were seeded overnight in appropriate culture media at 37°C in a humidified CO2 incubator. Conditioned media containing secreted cytokines/chemokines were profiled using RayBio human cytokine antibody arrayIIIand then analyzed and quantified using ImageJ software. In addition, using immunoblottingwe assessed the level of expression of total and phospho NF-kβ in leukocyte lysates from positive and negative LN patients.
Result: Flow cytometric analysis revealed a significant increase in the percentage of T lymphocytes and T helper(CD3+/CD4+) cells collected from axillary tributaries of positive LN patients as compared to negative LN patients. Leukocytesisolated from positive LN patients were characterized by more than five-foldincreases in IL-12, Thrombopoietin, IL-13, INF-ϒ, TARC, IGF-1, IL-3, TNF-α, IL-4, GCSF, IL-5 and IL-1α. Moreover, we detected an increase in cellular expression of total and phospho NF-kβ in leukocytes isolated from positive LN as compared to negative LN breast cancer patients.
Conclusion: Our results demonstrate for the first time that tumor-associated leukocytes of positive LN patients possess different cytokine patterns than those ofnegative LN patients. Moreover, we identified major cytokines that may contribute to LN metastasis and could be therapeutically targeted.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-05-11.
Collapse
Affiliation(s)
- EA ElGhonaimy
- Faculty of Science, Cairo University, Giza, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Wayne State University, Detroit, MI
| | - M El-Shinawi
- Faculty of Science, Cairo University, Giza, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Wayne State University, Detroit, MI
| | - R Abd-El-Tawab
- Faculty of Science, Cairo University, Giza, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Wayne State University, Detroit, MI
| | - T El Mamlouk
- Faculty of Science, Cairo University, Giza, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Wayne State University, Detroit, MI
| | - BF Sloane
- Faculty of Science, Cairo University, Giza, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Wayne State University, Detroit, MI
| | - MM Mohamed
- Faculty of Science, Cairo University, Giza, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Wayne State University, Detroit, MI
| |
Collapse
|
38
|
Kaur H, Mao S, Li Q, Sameni M, Krawetz SA, Sloane BF, Mattingly RR. RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. PLoS One 2012; 7:e50249. [PMID: 23236365 PMCID: PMC3516505 DOI: 10.1371/journal.pone.0050249] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2012] [Accepted: 10/22/2012] [Indexed: 01/16/2023] Open
Abstract
Breast ductal carcinoma in situ (DCIS) is being found in great numbers of women due to the widespread use of mammography. To increase knowledge of DCIS, we determined the expression changes that are common among three DCIS models (MCF10.DCIS, SUM102 and SUM225) compared to the MCF10A model of non-tumorigenic mammary epithelial cells in three dimensional (3D) overlay culture with reconstituted basement membrane (rBM). Extracted mRNA was subjected to 76 cycles of deep sequencing (RNA-Seq) using Illumina Genome Analyzer GAIIx. Analysis of RNA-Seq results showed 295 consistently differentially expressed transcripts in the DCIS models. These differentially expressed genes encode proteins that are associated with a number of signaling pathways such as integrin, fibroblast growth factor and TGFβ signaling, show association with cell-cell signaling, cell-cell adhesion and cell proliferation, and have a notable bias toward localization in the extracellular and plasma membrane compartments. RNA-Seq data was validated by quantitative real-time PCR of selected differentially expressed genes. Aldehyde dehydrogenase 5A1 (ALDH5A1) which is an enzyme that is involved in mitochondrial glutamate metabolism, was over-expressed in all three DCIS models at both the mRNA and protein levels. Disulfiram and valproic acid are known to inhibit ALDH5A1 and are safe for chronic use in humans for other disorders. Both of these drugs significantly inhibited net proliferation of the DCIS 3D rBM overlay models, but had minimal effect on MCF10A 3D rBM overlay models. These results suggest that ALDH5A1 may play an important role in DCIS and potentially serve as a novel molecular therapeutic target.
Collapse
Affiliation(s)
- Hitchintan Kaur
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
| | - Shihong Mao
- Center for Molecular Medicine and Genetics, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
| | - Quanwen Li
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
- Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States of America
| | - Mansoureh Sameni
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
| | - Stephen A. Krawetz
- Center for Molecular Medicine and Genetics, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
- Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States of America
| | - Bonnie F. Sloane
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
- Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States of America
| | - Raymond R. Mattingly
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, United States of America
- Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States of America
- * E-mail:
| |
Collapse
|
39
|
Strand DW, DeGraff DJ, Jiang M, Sameni M, Franco OE, Love HD, Hayward WJ, Lin-Tsai O, Wang AY, Cates JMM, Sloane BF, Matusik RJ, Hayward SW. Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am J Pathol 2012; 182:449-59. [PMID: 23219716 DOI: 10.1016/j.ajpath.2012.10.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2012] [Revised: 10/15/2012] [Accepted: 10/19/2012] [Indexed: 01/14/2023]
Abstract
Hindgut-derived endoderm can differentiate into rectal, prostatic, and bladder phenotypes. Stromal-epithelial interactions are crucial for this development; however, the precise mechanisms by which epithelium responds to stromal cues remain unknown. We have previously reported ectopic expression of peroxisome proliferator-activated receptor-γ2 (PPARγ2) increased androgen receptor expression and promoted differentiation of mouse prostate epithelium. PPARγ is also implicated in urothelial differentiation. Herein we demonstrate that knockdown of PPARγ2 in benign human prostate epithelial cells (BHPrEs) promotes urothelial transdifferentiation. Furthermore, in vitro and in vivo heterotypic tissue regeneration models with embryonic bladder mesenchyme promoted urothelial differentiation of PPARγ2-deficient BHPrE cells, and deficiency of both PPARγ isoforms 1 and 2 arrested differentiation. Because PTEN deficiency is cooperative in urothelial pathogenesis, we engineered BHPrE cells with combined knockdown of PPARγ and PTEN and performed heterotypic recombination experiments using embryonic bladder mesenchyme. Whereas PTEN deficiency alone induced latent squamous differentiation in BHPrE cells, combined PPARγ and PTEN deficiency accelerated the development of keratinizing squamous metaplasia (KSM). We further confirmed via immunohistochemistry that gene expression changes in metaplastic recombinants reflected human urothelium undergoing KSM. In summary, these data suggest that PPARγ isoform expression provides a molecular basis for observations that adult human epithelium can be transdifferentiated on the basis of heterotypic mesenchymal induction. These data also implicate PPARγ and PTEN inactivation in the development of KSM.
Collapse
Affiliation(s)
- Douglas W Strand
- Department of Urologic Surgery, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2765, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Reichenbach G, Starzinski-Powitz A, Sloane BF, Doll M, Kippenberger S, Bernd A, Kaufmann R, Meissner M. PPARα agonist Wy14643 suppresses cathepsin B in human endothelial cells via transcriptional, post-transcriptional and post-translational mechanisms. Angiogenesis 2012; 16:223-33. [PMID: 23096928 DOI: 10.1007/s10456-012-9314-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Accepted: 10/12/2012] [Indexed: 10/27/2022]
Abstract
Cathepsin B has been shown to be important in angiogenesis; therefore, understanding its regulation in endothelial cells should provide fundamental information that will aid in the development of new treatment options. Peroxisome proliferator-activated receptors (PPARs) have been shown to have anti-inflammatory, anti-angiogenic and anti-tumorigenic properties. We explored the influence of a PPARα agonist on cathepsin B expression in human endothelial cells. The PPARα agonist, Wy14643, was found to inhibit cathepsin B protein expression. Further studies demonstrated the Wy14643-dependent but PPARα-independent suppression of cathepsin B. This has been previously described for other PPAR agonists. Wy14643 suppressed the accumulation of cathepsin B mRNA, which was accompanied by the selective suppression of a 5'-alternative splice variant. Consistent with these results, luciferase promoter assays and electrophoretic mobility shift analysis demonstrated that the suppression was facilitated by reduced binding of the transcription factors USF1/2 to an E-box within the cathepsin B promoter. Additionally, Wy14643 treatment resulted in a reduction in cathepsin B half-life, suggesting a posttranslational regulatory mechanism. Overall, our results suggest that the PPARα-dependent anti-angiogenic action of Wy14643 seems to be mediated, in part, by Wy14643-dependent but PPARα-independent regulation of cathepsin B expression.
Collapse
Affiliation(s)
- Gabi Reichenbach
- Department of Dermatology, Venereology and Allergology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Affiliation(s)
- Bonnie F Sloane
- Department of Pharmacology and Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
| |
Collapse
|
42
|
Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, Lloyd MC, Sloane BF, Gillies RJ. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res 2012; 72:3938-47. [PMID: 22719070 DOI: 10.1158/0008-5472.can-11-3881] [Citation(s) in RCA: 178] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Tumor cell survival relies upon adaptation to the acidic conditions of the tumor microenvironment. To investigate potential acidosis survival mechanisms, we examined the effect of low pH (6.7) on human breast carcinoma cells. Acute low pH exposure reduced proliferation rate, induced a G1 cell cycle arrest, and increased cytoplasmic vacuolization. Gene expression analysis revealed elevated levels of ATG5 and BNIP3 in acid-conditioned cells, suggesting cells exposed to low pH may utilize autophagy as a survival mechanism. In support of this hypothesis, we found that acute low pH stimulated autophagy as defined by an increase in LC3-positive punctate vesicles, double-membrane vacuoles, and decreased phosphorylation of AKT and ribosomal protein S6. Notably, cells exposed to low pH for approximately 3 months restored their proliferative capacity while maintaining the cytoplasmic vacuolated phenotype. Although autophagy is typically transient, elevated autophagy markers were maintained chronically in low pH conditioned cells as visualized by increased protein expression of LC3-II and double-membrane vacuoles. Furthermore, these cells exhibited elevated sensitivity to PI3K-class III inhibition by 3-methyladenine. In mouse tumors, LC3 expression was reduced by systemic treatment with sodium bicarbonate, which raises intratumoral pH. Taken together, these results argue that acidic conditions in the tumor microenvironment promote autophagy, and that chronic autophagy occurs as a survival adaptation in this setting.
Collapse
Affiliation(s)
- Jonathan W Wojtkowiak
- Department of Cancer Imaging and Metabolism, Analytic Microscopy Core Facility, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Rothberg JM, Bogyo MS, Sloane BF. Abstract 2467: Acidic pericellular pH increases contribution of cathepsin B to invasiveness of a human breast carcinoma cell line. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-2467] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Among the non-cellular microenvironmental factors that may contribute to malignancy of solid tumors is an acidic peritumoral pH (pHe). We have shown that this induces secretion of the lysosomal cysteine protease, cathepsin B. The object of the present study was to further examine the effect of a slightly acidic pericellular pH (i.e., pHe 6.8) on degradation of collagen IV and the activity and secretion of proteolytic enzymes, in particular cathepsin B. For these studies, we used: 1) a highly malignant human breast carcinoma line, MDA-MB-231-RFP; 2) a 3D reconstituted basement membrane overlay culture model; 3) a live cell confocal microscopy assay for imaging proteolysis and detecting active cathepsin B via an activity based probe, GB123; 4) a protocol for quantification of proteolysis on a per cell basis; 5) and fluorometric real-time and plate-reader assays for measuring cathepsin B activity. The live cell proteolysis assay confirmed that degradation of collagen IV by the MDA-MB-231 cells was consistently higher at a slightly acidic pHe and was decreased by a highly selective cathepsin B inhibitor, CA074. A dramatic increase in cathepsin B secretion from MDA-MB-231 cells was observed upon exposure to an acidic pHe, as assessed by assays of conditioned media and analysis of secretion in real-time. Our results are consistent with the hypothesis by Gillies and colleagues of “acid-mediated invasion” in tumors and suggest a role for cathepsin B in promoting degradation of collagen IV and thereby tumor invasiveness in the acidic peritumoral microenvironment.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2467. doi:1538-7445.AM2012-2467
Collapse
|
44
|
Sameni M, Anbalagan A, Olive MB, Moin K, Mattingly RR, Sloane BF. MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression. J Vis Exp 2012:3661. [PMID: 22371028 DOI: 10.3791/3661] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
We have developed 3D coculture models, which we term MAME (mammary architecture and microenvironment engineering), and used them for live-cell imaging in real-time of cell:cell interactions. Our overall goal was to develop models that recapitulate the architecture of preinvasive breast lesions to study their progression to an invasive phenotype. Specifically, we developed models to analyze interactions among pre-malignant breast epithelial cell variants and other cell types of the tumor microenvironment that have been implicated in enhancing or reducing the progression of preinvasive breast epithelial cells to invasive ductal carcinomas. Other cell types studied to date are myoepithelial cells, fibroblasts, macrophages and blood and lymphatic microvascular endothelial cells. In addition to the MAME models, which are designed to recapitulate the cellular interactions within the breast during cancer progression, we have developed comparable models for the progression of prostate cancers. Here we illustrate the procedures for establishing the 3D cocultures along with the use of live-cell imaging and a functional proteolysis assay to follow the transition of cocultures of breast ductal carcinoma in situ (DCIS) cells and fibroblasts to an invasive phenotype over time, in this case over twenty-three days in culture. The MAME cocultures consist of multiple layers. Fibroblasts are embedded in the bottom layer of type I collagen. On that is placed a layer of reconstituted basement membrane (rBM) on which DCIS cells are seeded. A final top layer of 2% rBM is included and replenished with every change of media. To image proteolysis associated with the progression to an invasive phenotype, we use dye-quenched (DQ) fluorescent matrix proteins (DQ-collagen I mixed with the layer of collagen I and DQ-collagen IV mixed with the middle layer of rBM) and observe live cultures using confocal microscopy. Optical sections are captured, processed and reconstructed in 3D with Volocity visualization software. Over the course of 23 days in MAME cocultures, the DCIS cells proliferate and coalesce into large invasive structures. Fibroblasts migrate and become incorporated into these invasive structures. Fluorescent proteolytic fragments of the collagens are found in association with the surface of DCIS structures, intracellularly, and also dispersed throughout the surrounding matrix. Drugs that target proteolytic, chemokine/cytokine and kinase pathways or modifications in the cellular composition of the cocultures can reduce the invasiveness, suggesting that MAME models can be used as preclinical screens for novel therapeutic approaches.
Collapse
|
45
|
Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 2012; 72:1199-209. [PMID: 22266111 DOI: 10.1158/0008-5472.can-11-2759] [Citation(s) in RCA: 146] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Metastasis to bone is a major cause of morbidity in breast cancer patients, emphasizing the importance of identifying molecular drivers of bone metastasis for new therapeutic targets. The endogenous cysteine cathepsin inhibitor stefin A is a suppressor of breast cancer metastasis to bone that is coexpressed with cathepsin B in bone metastases. In this study, we used the immunocompetent 4T1.2 model of breast cancer which exhibits spontaneous bone metastasis to evaluate the function and therapeutic targeting potential of cathepsin B in this setting of advanced disease. Cathepsin B abundancy in the model mimicked human disease, both at the level of primary tumors and matched spinal metastases. RNA interference-mediated knockdown of cathepsin B in tumor cells reduced collagen I degradation in vitro and bone metastasis in vivo. Similarly, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a reduction that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt. Notably, metastasis suppression by CA-074 was maintained in a late treatment setting, pointing to a role in metastatic outgrowth. Together, our findings established a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benefits of its selective inhibition in vivo.
Collapse
Affiliation(s)
- Nimali P Withana
- Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 2012. [PMID: 22266111 DOI: 10.1158/0008-5472.can-11-27590008-5472.can-11-2759] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Metastasis to bone is a major cause of morbidity in breast cancer patients, emphasizing the importance of identifying molecular drivers of bone metastasis for new therapeutic targets. The endogenous cysteine cathepsin inhibitor stefin A is a suppressor of breast cancer metastasis to bone that is coexpressed with cathepsin B in bone metastases. In this study, we used the immunocompetent 4T1.2 model of breast cancer which exhibits spontaneous bone metastasis to evaluate the function and therapeutic targeting potential of cathepsin B in this setting of advanced disease. Cathepsin B abundancy in the model mimicked human disease, both at the level of primary tumors and matched spinal metastases. RNA interference-mediated knockdown of cathepsin B in tumor cells reduced collagen I degradation in vitro and bone metastasis in vivo. Similarly, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a reduction that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt. Notably, metastasis suppression by CA-074 was maintained in a late treatment setting, pointing to a role in metastatic outgrowth. Together, our findings established a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benefits of its selective inhibition in vivo.
Collapse
Affiliation(s)
- Nimali P Withana
- Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Proteases play causal roles in many aspects of the aggressive phenotype of tumors, yet many of the implicated proteases originate from tumor-associated cells or from responses of tumor cells to interactions with other cells. Therefore, to obtain a comprehensive view of tumor proteases, we need to be able to assess proteolysis in tumors that are interacting with their microenvironment. As this is difficult to do in vivo, we have developed functional live-cell optical imaging assays and 3D and 4D (i.e., 3D over time) coculture models. We present here a description of the probes used to measure proteolysis and protease activities, the methods used for imaging and analysis of proteolysis and the 3D and 4D models used in our laboratory. Of course, all assays have limitations; however, we suggest that the techniques discussed here will, with attention to their limitations, be useful as a screen for drugs to target the invasive phenotype of tumors.
Collapse
Affiliation(s)
- Kamiar Moin
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan, USA
| | | | | | | | | | | |
Collapse
|
48
|
Rothberg JM, Sameni M, Moin K, Sloane BF. Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. Biochim Biophys Acta 2012; 1824:123-32. [PMID: 21854877 PMCID: PMC3232330 DOI: 10.1016/j.bbapap.2011.07.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2011] [Revised: 07/28/2011] [Accepted: 07/29/2011] [Indexed: 01/26/2023]
Abstract
Our laboratory has had a longstanding interest in how the interactions between tumors and their microenvironment affect malignant progression. Recently, we have focused on defining the proteolytic pathways that function in the transition of breast cancer from the pre-invasive lesions of ductal carcinoma in situ (DCIS) to invasive ductal carcinomas (IDCs). We use live-cell imaging to visualize, localize and quantify proteolysis as it occurs in real-time and thereby have established roles for lysosomal cysteine proteases both pericellularly and intracellularly in tumor proteolysis. To facilitate these studies, we have developed and optimized 3D organotypic co-culture models that recapitulate the in vivo interactions of mammary epithelial cells or tumor cells with stromal and inflammatory cells. Here we will discuss the background that led to our present studies as well as the techniques and models that we employ. This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome.
Collapse
MESH Headings
- Animals
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Intraductal, Noninfiltrating/metabolism
- Carcinoma, Intraductal, Noninfiltrating/pathology
- Cells, Cultured
- Cellular Microenvironment/physiology
- Diagnostic Imaging/methods
- Female
- Humans
- Microscopy, Video
- Models, Biological
- Neoplasms/diagnosis
- Neoplasms/metabolism
- Neoplasms/pathology
- Proteolysis
- Single-Cell Analysis/methods
- Tumor Microenvironment/physiology
Collapse
Affiliation(s)
- Jennifer M Rothberg
- Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
| | | | | | | |
Collapse
|
49
|
Wojtkowiak JW, Sane KM, Kleinman M, Sloane BF, Reiners JJ, Mattingly RR. Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin. J Pharmacol Exp Ther 2011; 337:65-74. [PMID: 21228063 DOI: 10.1124/jpet.110.174573] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Exposure of the human malignant peripheral nerve sheath tumor cell lines STS-26T, ST88-14, and NF90-8 to nanomolar concentrations of both lovastatin and farnesyl transferase inhibitor (FTI)-1 but not to either drug alone induced cell death. ST88-14 and NF90-8 cells underwent apoptosis, yet dying STS-26T cells did not. FTI-1 cotreatment induced a strong and sustained autophagic response as indicated by analyses of microtubule-associated protein-1 light chain 3 (LC3)-II accumulation in STS-26T cultures. Extensive colocalization of LC3-positive punctate spots was observed with both lysosome-associated membrane protein (LAMP)-1 and LAMP-2 (markers of late endosomes/lysosomes) in solvent or FTI-1 or lovastatin-treated STS-26T cultures but very little colocalization in lovastatin/FTI-1-cotreated cultures. The absence of colocalization in the cotreatment protocol correlated with loss of LAMP-2 expression. Autophagic flux studies indicated that lovastatin/FTI-1 cotreatment inhibited the completion of the autophagic program. In contrast, rapamycin induced an autophagic response that was associated with cytostasis but maintenance of viability. These studies indicate that cotreatment of STS-26T cells with lovastatin and FTI-1 induces an abortive autophagic program and nonapoptotic cell death.
Collapse
Affiliation(s)
- Jonathan W Wojtkowiak
- Department of Pharmacology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
| | | | | | | | | | | |
Collapse
|
50
|
Nouh MA, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, Khaled HM, Sloane BF. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med 2011. [PMID: 21199580 DOI: 10.1186/1479-5876-9-11479-5876-9-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. In non-IBC, the cysteine protease cathepsin B (CTSB) is known to be involved in cancer progression and invasion; however, very little is known about its role in IBC. METHODS In this study, we enrolled 23 IBC and 27 non-IBC patients. All patient tissues used for analysis were from untreated patients. Using immunohistochemistry and immunoblotting, we assessed the levels of expression of CTSB in IBC versus non-IBC patient tissues. Previously, we found that CTSB is localized to caveolar membrane microdomains in cancer cell lines including IBC, and therefore, we also examined the expression of caveolin-1 (cav-1), a structural protein of caveolae in IBC versus non-IBC tissues. In addition, we tested the correlation between the expression of CTSB and cav-1 and the number of positive metastatic lymph nodes in both patient groups. RESULTS Our results revealed that CTSB and cav-1 were overexpressed in IBC as compared to non-IBC tissues. Moreover, there was a significant positive correlation between the expression of CTSB and the number of positive metastatic lymph nodes in IBC. CONCLUSIONS CTSB may initiate proteolytic pathways crucial for IBC invasion. Thus, our data demonstrate that CTSB may be a potential prognostic marker for lymph node metastasis in IBC.
Collapse
Affiliation(s)
- Mohamed A Nouh
- Department of Pathology, National Cancer Institute, Cairo University, Giza 12613 Egypt
| | | | | | | | | | | | | |
Collapse
|